Japanese / English

Research Collaboration

Our advantage

Drugs that only Nippon Shinyaku can make
A future that only Nippon Shinyaku can create

Nippon Shinyaku has gained extensive experience in our focused therapeutic areas. Thanks to our research and development achievement and sales performance in the urology, hematology and intractable/orphan disease fields, we have built up trust with the stakeholder. In 2016, we launched our original drug Uptravi® for the treatment of pulmonary arterial hypertension (PAH). Uptravi® is an orally available selective IP prostacyclin receptor agonist and is the first such drug in the world. Uptravi® is now being used to treat PAH patients around the world.

Nippon Shinyaku aims to create effective therapeutic agents for intractable diseases that have yet to find an effective treatment, and the Nucleic acid drug research is our most distinct engagement. We have been focusing on this field and its applications to next-generation drugs for more than 20 years. Now we have developed Viltepso® (NS-065/NCNP-01) for the treatment of Duchenne muscular dystrophy (DMD) by collaborative research with the National Center of Neurology and Psychiatry (NCNP). Viltepso® (NS-065/NCNP-01) received SAKIGAKE designation from the Ministry of Health, Labour and Welfare (MHLW), and was launched in Japan in May 2020 as the first approved antisense nucleic acid drug of Japan original. It was granted for fast track, orphan drug, and rare pediatric disease designations from the FDA, and was launched in the US in August 2020. Also, we have submitted its New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China in June 2021.

Our achievements and experience are supported by the enthusiasm of our employees, who wish to provide new drugs to patients struggling with illness as soon as possible. We share the same goal with you and we will develop new drugs with sincerity.